The effect of tiotropium in combination with olodaterol on house dust mite-induced allergic airway disease

Publication date: Available online 5 July 2017 Source:Pulmonary Pharmacology & Therapeutics Author(s): Gerrit John-Schuster, Stan de Kleijn, Yolanda van Wijck, Veerle Kremer, Hermelijn H. Smits, Michael P. Pieper, Pieter S. Hiemstra, Christian Taube One of the major goals of asthma therapy is to maintain asthma control and prevent acute exacerbations. Long-acting bronchodilators are regularly used for the treatment of asthma patients and in clinical studies the anti-cholinergic tiotropium has recently been shown to reduce exacerbations in patients with asthma. So far it is unclear how tiotropium exerts this effect. For this purpose, we designed an allergen-driven rechallenge model of allergic airway inflammation in mice, to assess the effectiveness of tiotropium and the long-acting β-2 adrenoceptor agonist olodaterol on allergen-induced exacerbations of airway disease. Female C57BL/6J mice were sensitized intranasally (i.n.) with 1 μg of house dust mite (HDM) extract followed by a challenge regime (5 consecutive days 10 μg HDM extract i.n.) after one week. Mice were exposed to a secondary challenge five weeks after sensitization and were treated i.n. with different concentrations of tiotropium or olodaterol (1, 10 and 100 μg/kg) or a combination thereof (10 μg/kg each) prior to and during the secondary challenge period. Three days after the last challenge, bronchoalveolar lavage (BAL) fluid and lung tissue were collected for flow cytometry and histo...
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research